Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 357

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial

Open access
Vincent, Jean-Louis, Francois, Bruno, Zabolotskikh, Igor, Daga, Mradul Kumar, Lascarrou, Jean-Baptiste, Kirov, Mikhail Y., Pettilä, Ville, Wittebole, Xavier, Meziani, Ferhat, Mercier, Emmanuelle, Lobo, Suzana M., Barie, Philip S., Crowther, Mark, Esmon, Charles T., Fareed, Jawed, Gando, Satoshi, Gorelick, Kenneth J., Levi, Marcel, Mira, Jean-Paul, Opal, Steven M., Parrillo, Joseph, Russell, James A., Saito, Hidehiko, Tsuruta, Kazuhisa, Sakai, Takumi, Fineberg, David, for the SCARLET Trial Group · 2019 · JAMA

Abstract

Importance: Previous research suggested that soluble human recombinant thrombomodulin may reduce mortality among patients with sepsis-associated coagulopathy. Objective: To determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality among patients with sepsis-associated coagulopathy. Design, Setting, and Participants: The SCARLET trial was a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 countries. All adult patients admitted to one of the participating intensive care units between October 2012 and March 2018 with sepsis-associated coagulopathy and concomitant cardiovascular and/or respiratory failure, defined as an international normalized ratio greater than 1.40 without other known etiology and a platelet count in the range of 30 to 150 × 109/L or a greater than 30% decrease in platelet count within 24 hours, were considered for inclusion. The final date of follow-up was February 28, 2019. Interventions: Patients with sepsis-associated coagulopathy were randomized and treated with an intravenous bolus or a 15-minute infusion of thrombomodulin (0.06 mg/kg/d [maximum, 6 mg/d]; n = 395) or matching placebo (n = 405) once daily for 6 days. Main Outcome and Measures: The primary end point was 28-day all-cause mortality. Results: Among 816 randomized patients, 800 (mean age, 60.7 years; 437 [54.6%] men) completed the study and were included in the full analysis set. In these patients, the 28-day all-cause mortality rate was not statistically significantly different between the thrombomodulin group and the placebo group (106 of 395 patients [26.8%] vs 119 of 405 patients [29.4%], respectively; P = .32). The absolute risk difference was 2.55% (95% CI, -3.68% to 8.77%). The incidence of serious major bleeding adverse events (defined as any intracranial hemorrhage; life-threatening bleeding; or bleeding event classified as serious by the investigator, with administration of at least 1440 mL [typically 6 units] of packed red blood cells over 2 consecutive days) was 23 of 396 patients (5.8%) in the thrombomodulin group and 16 of 404 (4.0%) in the placebo group. Conclusions and Relevance: Among patients with sepsis-associated coagulopathy, administration of a human recombinant thrombomodulin, compared with placebo, did not significantly reduce 28-day all-cause mortality. Trial Registration: ClinicalTrials.gov Identifier: NCT01598831.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2019.5358

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 357

Metadata

Authors
Vincent, J.-L., Francois, B., Zabolotskikh, I., Daga, M. K., Lascarrou, J.-B., Kirov, M. Y., Pettilä, V., Wittebole, X., Meziani, F., Mercier, E., Lobo, S. M., Barie, P. S., Crowther, M., Esmon, C. T., Fareed, J., Gando, S., Gorelick, K. J., Levi, M., Mira, J.-P., Opal, S. M., Parrillo, J., Russell, J. A., Saito, H., Tsuruta, K., Sakai, T., Fineberg, D., & for the SCARLET Trial Group
Venue
JAMA
Published
2019-05-28
Volume
321
Issue
20
Pages
1993
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2946375103
Cited by
357
References
9
FWCI
29.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2019.5358
The paper
Vincent, J.-L., Francois, B., Zabolotskikh, I., Daga, M. K., Lascarrou, J.-B., Kirov, M. Y., Pettilä, V., Wittebole, X., Meziani, F., Mercier, E., Lobo, S. M., Barie, P. S., Crowther, M., Esmon, C. T., Fareed, J., Gando, S., Gorelick, K. J., Levi, M., Mira, J.-P., . . . for the SCARLET Trial Group. (2019). Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2019.5358

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.